Korean drugmaker best known for eye drops, developing an Eylea biosimilar and oral GLP-1 and long-acting injectable drugs.
Korean drugmaker best known for eye drops, developing an Eylea biosimilar and oral GLP-1 and long-acting injectable drugs.
Earns mainly from ophthalmic (eye) products, about half of sales, plus cardiovascular and antibiotic drugs, and exports eye drops to Europe and the US. Its next growth step is an Eylea biosimilar (a near-copy of a biologic drug) sold through partners, Fresenius Kabi in the US and Apotex in Canada, after an August 2026 patent settlement with Regeneron and Bayer.
Moat: narrow (process know-how, regulatory licence). EU-GMP-certified eye-drop manufacturing and partnered biosimilar sales; many Korean and global drugmakers compete.
Headquarters: Seoul, South Korea · Founded: 1943 · Employees: 436
Size Sam Chun Dang Pharm (000250.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $2.36B, the 123rd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩137,300 on 18 Nov 2026.
Performance Over six months the shares fell 66.1%, against -9.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 22.8% over the last twelve months (peer median +0.1%); the operating margin is 6.6% (peer median 11.1%).
Valuation It trades at 11.8× enterprise value to sales against a peer median of 4.2× (8th most expensive of 20).
Capital Return on invested capital runs 5.8 points below its cost of capital (8.7% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩271B | ₩232B | ₩211B | ₩193B | ₩177B |
| Revenue growth | — | +10% | +9% | +9% | — |
| Gross profit | ₩124B | ₩106B | ₩97.0B | ₩94.5B | ₩87.9B |
| EBITDA | ₩30.6B | ₩19.3B | ₩26.0B | ₩18.1B | ₩20.2B |
| Net income | ₩13.4B | ₩5.26B | -₩10.9B | -₩10.4B | ₩5.84B |
| Free cash flow | -₩24.3B | -₩36.4B | ₩4.75B | ₩16.7B | -₩3.25B |
| Capital expenditure | ₩64.2B | ₩59.6B | ₩41.3B | ₩22.0B | ₩46.5B |
| Total debt | ₩60.9B | ₩69.8B | ₩49.9B | ₩53.6B | ₩76.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Sam Chun Dang Pharm 000250.KS | $2.36B | -66% | +23% | 7% | 11.8× | n/a |
| Santen Pharmaceutical 4536.T | $4.14B | +10% | +2% | 16% | 2.0× | -5.0% |
| Celltrion 068270.KS | $34.9B | +12% | +40% | 32% | 9.0× | 10.6% |
| Alvotech ALVO | $1.62B | +38% | -14% | 12% | 6.4× | n/a |
| Formycon FYB.DE | n/a | -28% | n/a | n/a | n/a | n/a |
| HanmiPharm 128940.KS | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000250.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -33.0% | -4.4% | 2nd lowest of 21 |
| 6-month return | -66.1% | -9.7% | 2nd lowest of 21 |
| Distance from 52-week high | -88.9% | -28.5% | 2nd lowest of 21 |
| Revenue growth (TTM) | +22.8% | +0.1% | 6th highest of 20 |
| Operating margin | 6.6% | 11.1% | 8th lowest of 19 |
| EV / Sales | 11.8× | 4.2× | 8th most expensive of 20 |
| ROIC minus cost of capital | -5.8 pp | -1.3 pp | 4th lowest of 15 |
| Net debt / EBITDA | -1.3× | 0.4× | 2nd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | 11.8× | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | 67.0× | n/a | n/a |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 1.3× | 14.1% | +0.8% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 2.0× | 47.0% | +19.3% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 16.8× | n/a | n/a |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 13.6× | 37.9% | +22.9% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 3.8× | 2.3% | +2.9% |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 14.0× | 41.3% | +27.7% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 1.9× | 6.1% | +6.5% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | 1.5× | -2.5% | -5.8% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 4.2× | 3.4% | +4.8% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 2.6× | 26.7% | +6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 4.2× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 1.7× | -9.7% | -1.5% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | 48.0× | n/a | n/a |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | 3.3× | n/a | n/a |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 4.0× | -11.0% | +37.6% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 25.1× | 25.5% | +100.1% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 8.4× | 3.2% | +15.7% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 12.9× | 37.4% | +6.1% |